vast
major
infecti
diseas
speci
initi
colon
entri
across
mucos
surfac
respiratori
intestin
urogenit
tract
therefor
great
deal
interest
immun
respons
site
develop
vaccin
target
portal
entri
hodgin
et
al
realiti
current
vaccin
infect
deliv
parenter
act
thorough
induct
system
rather
mucos
immun
protect
typic
mediat
spillov
mediat
onto
mucos
surfac
block
infect
mucos
surfac
breach
exampl
includ
vaccin
influenza
virus
vibrio
salmonella
veterinari
immunolog
immunopatholog
r
c
l
e
n
f
mucos
immun
vaccin
mannheimia
haemolytica
cattl
b
r
c
recognit
mucos
portal
entri
mani
infecti
diseas
relev
mucos
immun
respons
protect
encourag
develop
vaccin
administ
mucos
rout
princip
oral
intranas
stimul
intestin
nasopharyng
lymphoid
tissu
respect
oral
rout
problemat
cattl
rumin
antigen
degrad
rumen
like
prior
transit
intestin
hand
rumin
exploit
exposur
nasopharyng
tissu
cud
vaccin
antigen
express
fibrou
feed
like
alfalfa
increas
antileukotoxin
lkt
iga
demonstr
nasal
secret
calv
follow
feed
alfalfa
express
truncat
mannheimia
haemolytica
evid
suggest
vaccin
may
protect
experiment
induc
pneumonia
intranas
vaccin
altern
approach
use
prerumin
calv
intranas
administr
iscom
carri
solubl
antigen
haemolytica
includ
nativ
lkt
induc
lkt
specif
iga
nasal
secret
vaccin
week
age
subcutan
sc
administr
vaccin
induc
lkt
specif
igg
serum
nasal
secret
wherea
sc
administr
commerci
haemolytica
vaccin
regardless
vaccin
strategi
employ
difficult
assess
immunogen
mucos
administ
vaccin
product
secret
antibodi
tend
transient
persist
mucos
surfac
absenc
ongo
antigen
stimul
addit
challeng
demonstr
vaccin
efficaci
respons
experiment
infect
protect
mucos
vaccin
anim
probabl
result
recal
respons
may
amplifi
suffici
counter
effect
experiment
pulmonari
deliveri
larg
bolu
virul
bacteria
even
though
respons
would
suffic
prolong
gradual
infect
occur
natur
induct
pneumonia
elsevi
bv
right
reserv
corbeil
et
al
wilki
markham
despit
success
develop
mucos
deliv
vaccin
remain
area
activ
investig
mani
laboratori
human
veterinari
pathogen
vaccin
mucos
immun
mediat
immunoglobulin
effector
cell
gener
mucos
exposur
antigen
differ
gener
system
immun
boyaka
et
al
certainli
goal
prevent
infect
presenc
mediat
mucos
surfac
need
memori
cell
gener
mucos
site
drain
lymph
node
home
preferenti
mucos
locat
provid
prime
respons
potenti
portal
exposur
youngman
et
al
also
nonimmunologl
reason
seek
vaccin
deliv
without
inject
includ
eas
deliveri
absenc
inject
site
reaction
vaccin
food
produc
anim
would
facilit
mass
deliveri
vaccin
feed
water
aerosol
mean
less
labor
cost
produc
reduc
stress
anim
addit
carcass
condemn
due
needl
breakag
inject
site
reaction
would
avoid
roeber
et
al
increas
consum
pressur
organ
produc
food
natur
approach
diseas
manag
compat
diseas
prevent
use
noninvas
method
vaccin
deliveri
mucos
deliveri
antigen
trigger
immun
respons
mucosaassoci
lymphoid
tissu
includ
peyer
patch
small
intestin
tonsil
associ
pharyng
lymphoid
tissu
bronchu
associ
lymphoid
tissu
lung
diffus
lymphoid
aggreg
line
urogenti
tract
induct
site
mucos
immun
thoroughli
describ
intestin
tract
antigen
deliv
underli
peyer
patch
special
membran
noncili
epitheli
cell
cell
locat
villou
crypt
dendrit
cell
dc
send
process
surfac
ciliat
columnar
epitheli
cell
villi
dc
deliv
antigen
peyer
patch
drain
mesenter
node
meeusen
et
al
similar
mechan
antigen
acquisit
exist
mucos
site
includ
tonsilar
crypt
balt
cell
epitheli
dc
identifi
gebert
pabst
stanley
et
al
presum
also
genit
site
hodgin
et
al
experiment
calv
immun
vulvovagin
rectal
rout
loehr
et
al
loehr
et
al
mucos
vaccin
deliv
antigen
oral
administr
target
intestin
induct
intranas
target
pharyng
depend
particl
size
deeper
respiratori
tissu
mani
challeng
inher
mucos
antigen
deliveri
intranas
vaccin
must
deliv
dosag
suffici
overcom
innat
clearanc
mechan
facilit
uptak
pharynx
oral
vaccin
must
protect
degrad
digest
process
mechan
need
facilit
antigen
adher
mucos
epithelium
avoid
clearanc
mucociliari
blanket
coat
gut
potenti
induct
toler
rather
activ
immun
must
consid
mous
model
oral
deliveri
autoantigen
may
lead
oral
toler
revers
reduct
autoimmun
howev
oral
toler
yet
report
studi
plant
express
antigen
deliv
vaccin
mice
monogastr
anim
arntzen
et
al
rice
et
al
success
oral
vaccin
exist
vaccin
polio
rabi
excel
exampl
vaccin
use
avirul
live
bacteria
eg
salmonella
bordetella
virus
eg
adenoviru
coronaviru
reoviru
shown
quit
effect
stimul
mucos
immun
respons
case
vaccin
organ
least
minim
invas
system
respons
well
perhap
greatest
challeng
mucos
immun
lie
vaccin
nonrepl
antigen
prepar
difficult
protect
digest
tend
adher
mucos
surfac
gener
fail
trigger
danger
signal
need
initi
appropri
cellular
stimul
activ
immun
respons
experiment
sever
strategi
employ
overcom
inher
challeng
vaccin
antigen
enclos
within
microspher
link
bacteri
toxin
subunit
ct
lt
administ
molecul
induc
danger
signal
like
cpg
motif
cytokin
stimul
lymphocyt
activ
holmgren
et
al
rumin
anim
pose
particular
challeng
develop
oral
administ
vaccin
encapsul
antigen
polym
microparticl
microspher
resist
digest
rumen
one
approach
show
promis
stimul
mucos
immun
respons
peyer
patch
oral
deliveri
bowersock
et
al
altern
approach
exploit
process
rumin
exposur
pharyng
lymphoid
tissu
includ
tonsil
cud
could
particularli
valuabl
approach
vaccin
respiratori
intestin
diseas
sinc
recogn
memori
cell
produc
tonsilar
lymphoid
tissu
migrat
preferenti
lung
intestin
prime
site
subsequ
natur
exposur
brandtzaeg
johansen
mind
hypothes
deliveri
protect
antigen
palat
fibrou
feed
alfalfa
could
lead
repeat
exposur
pharyng
lymphoid
tissu
cud
rumin
relev
econom
import
diseas
cattl
select
bovin
pneumon
pasteurellosi
target
diseas
studi
extens
experi
immun
princip
caus
bacterium
mannheimia
haemolytica
protect
antigen
made
appropri
conveni
model
system
test
immunogen
efficaci
edibl
vaccin
compris
transgen
alfalfa
first
antigen
target
research
leukotoxin
lkt
mani
studi
demonstr
lkt
import
pathogenesi
correl
presenc
antilkt
antibodi
serum
protect
pneumonia
howev
suggest
antilkt
respons
essenti
suffici
alon
provid
immun
shewen
wilki
jeyaseelan
et
al
transgen
alfalfa
use
experi
express
truncat
form
leukotoxin
contain
neutral
epitop
lee
et
al
concentr
least
mgg
dri
plant
materi
estim
percentag
total
solubl
protein
posttransl
modif
protein
occur
plant
gomord
fay
includ
nlink
olink
glycosyl
plant
glycosyl
pattern
differ
found
bacteria
sinc
extent
glycosyl
type
glycan
ad
protein
alter
immunogen
earli
step
work
demonstr
immunogen
plant
express
follow
intramuscular
inocul
rabbit
verif
antisera
immun
rabbit
recogn
recombin
nativ
lkt
lee
et
al
use
transgen
alfalfa
vehicl
provid
effici
mean
deliveri
antigen
also
furnish
protect
immedi
dilut
destruct
rumen
natur
process
cud
mean
fibrou
feed
regurgit
chew
slowli
held
cud
posterior
oral
caviti
typic
activ
occur
time
period
sever
day
spray
pharyng
lymphoid
tissu
antigen
cycl
final
digest
pass
system
concern
deliveri
avoid
innat
clearanc
mechan
antigen
destruct
address
least
two
major
challeng
remain
barrier
vaccin
develop
first
demonstr
immunogen
anticip
respons
predomin
mucos
therefor
inher
difficult
sampl
transient
absenc
continu
antigen
stimul
also
quit
possibl
pharyng
exposur
mere
prime
lung
anamnest
respons
infect
rather
lead
product
mucos
antibodi
respons
level
antigen
deliv
vaccin
second
relat
challeng
demonstr
efficaci
given
protect
like
deriv
recal
respons
respons
suffic
natur
exposur
sinc
gradual
continu
period
hour
day
easili
overwhelm
experiment
challeng
success
challeng
model
use
intrabronchi
deliveri
larg
number
organ
suffici
caus
pneumonia
singl
bolu
determin
extent
challeng
address
relat
question
dose
durat
feed
need
immun
conduct
seri
pilot
studi
feed
transgen
alfalfa
small
group
calv
typic
two
vaccin
two
control
receiv
equal
amount
wild
type
alfalfa
lieu
transgen
feed
initi
studi
opt
use
colostrum
depriv
anim
rear
isol
facil
avoid
interfer
passiv
matern
antibodi
minim
commens
colon
haemolytica
might
confound
demonstr
respons
vaccin
anim
germfre
caesarian
deriv
thu
low
level
colon
low
baselin
antibodi
titer
serum
time
first
feed
typic
month
age
experi
conduct
approv
univers
guelph
anim
care
committe
adher
canadian
council
anim
care
guidelin
use
anim
research
growth
process
storag
feed
transgen
alfalfa
well
dispos
anim
anim
wast
specifi
letter
permiss
canadian
food
inspect
agenc
respons
regul
gmo
use
experiment
vaccin
earli
trial
calv
fed
two
round
g
dri
alfalfa
day
day
interv
challeng
approxim
week
second
feed
intrabronchi
administr
ml
haemolytica
atcc
approxim
cfu
ml
dose
estim
caus
infect
suffici
elicit
recal
respons
produc
pneumonia
control
calv
euthan
day
postchalleng
mononuclear
cell
harvest
blood
tonsil
spleen
retropharyng
bronchial
mesenter
lymph
node
serum
nasal
swab
collect
variou
point
throughout
trial
presenc
antibodi
determin
lkt
specif
elisa
use
either
alfalfa
express
nativ
leukotoxin
log
phase
serumfre
cultur
supernat
antigen
latter
elisa
adapt
elispot
assay
detect
antibodi
secret
cell
mononuclear
cell
prepar
follow
incub
nativ
leukotoxin
mononuclear
cell
cultur
supernat
also
assay
product
interferon
gamma
use
commerci
kit
bovigam
pfizer
studi
note
feed
transgen
alfalfa
led
increas
lkt
specif
iga
nasal
secret
week
follow
second
feed
fig
increas
transient
time
challeng
level
specif
nasal
iga
similar
vaccin
control
chang
serum
antibodi
observ
prior
challeng
low
level
intrabronchi
challeng
haemolytica
cfuml
result
increas
serum
nasal
antibodi
calv
day
postchalleng
observ
illustr
difficulti
demonstr
humor
immun
respons
mucos
vaccin
respons
like
local
system
transient
thu
sampl
site
time
becom
critic
similar
respons
vaccin
recent
observ
larger
scale
feed
trial
colostrum
suffici
calv
vaccin
control
fig
baselin
serum
antibodi
lkt
higher
calv
previous
observ
colostrum
depriv
anim
feed
result
notic
chang
serum
antibodi
sever
calv
fed
recombin
alfalfa
maintain
elev
nasal
iga
lkt
week
second
feed
day
challeng
respons
sustain
anim
may
characterist
convent
calv
sinc
continu
antigen
stimul
due
natur
exposur
could
help
maintain
respons
enhanc
vaccin
experi
challeng
ml
haemolytica
cfuml
intend
induc
pneumonia
correl
level
antilkt
nasal
iga
protect
pneumonia
observ
howev
also
correl
level
antilkt
igg
serum
protect
even
though
could
demonstr
effect
vaccin
circul
level
antibodi
thu
despit
encourag
nasal
antibodi
result
confid
associ
protect
vaccin
one
pilot
studi
challeng
dose
cfu
ml
suffici
induc
pneumonia
two
control
calv
lesion
score
pneumon
tissu
calv
fed
alfalfa
express
clinic
sign
pneumonia
lesion
necropsi
although
caution
must
exercis
interpret
evid
vaccin
efficaci
sinc
calf
number
small
sever
interest
observ
made
respect
respons
mononuclear
cell
suscept
versu
resist
calv
vaccin
calv
lkt
specif
antibodi
produc
cell
day
old
cultur
cell
deriv
blood
bronchial
node
harvest
necropsi
evid
class
switch
sinc
iga
produc
cell
present
well
cell
produc
igm
control
calv
singl
blood
cell
produc
antibodi
one
igm
one
iga
interferon
gamma
product
blood
mononuclear
cell
calv
respons
tonsil
cell
weak
differenti
vaccin
control
calv
ifng
respons
bronchial
node
cell
spleen
retropharyng
node
cell
vaccin
produc
ifng
rapidli
within
h
incub
wherea
cell
control
calv
respond
later
strike
differ
observ
cultur
cell
mesenter
node
lkt
cell
vaccin
respond
produc
ifng
control
fig
especi
interest
sinc
challeng
pulmonari
intestin
thu
one
would
expect
activ
lymphocyt
node
confirm
traffick
antigenspecif
memori
cell
follow
exposur
nasopharynx
transgen
alfalfa
suggest
vaccin
antigen
surviv
rumin
sensit
galt
transport
across
intestin
epithelium
question
remain
address
least
identifi
tissu
target
ongo
investig
edibl
format
futur
veterinari
vaccin
rumin
anim
perhap
even
approach
succe
address
question
pneumonia
younger
calv
yet
rumin
bacteria
pasteurellacea
famili
major
contributor
enzoot
pneumonia
occur
week
age
veal
calv
replac
dairi
heifer
van
donkersgo
et
al
mucos
deliveri
vaccin
also
relev
goal
neonat
particular
intranas
deliveri
appeal
logist
eas
deliveri
immunolog
target
nasopharyng
lymphoid
tissu
per
fig
iga
antibodi
leukotoxin
lkt
nasal
secret
determin
elisa
assay
use
alfalfa
express
lkt
antigen
od
optic
densiti
alfalfa
minu
od
use
mock
antigen
prepar
deriv
alfalfa
express
gfp
grid
span
feed
day
solid
vertic
bar
indic
day
challeng
oval
indic
increas
specif
iga
day
feed
vaccin
calv
vaccin
control
group
mean
iga
antibodi
leukotoxin
nasal
swab
obtain
calv
fed
alfalfa
express
control
calv
fed
wildtyp
median
sampl
posit
sp
ratio
determin
elisa
assay
use
nativ
lkt
antigen
grid
span
feed
day
solid
vertic
bar
indic
day
challeng
spectiv
ad
difficulti
calv
age
potenti
interfer
activ
immun
respons
passiv
matern
antibodi
fact
pneumonia
week
age
occur
precis
period
passiv
immun
wane
extent
longer
protect
effect
interfer
activ
immun
respons
delay
gener
protect
immun
prado
et
al
previous
demonstr
calv
produc
leukotoxin
neutral
antibodi
respons
parenter
vaccin
commerci
haemolytica
cultur
supernat
vaccin
prespons
wyethfort
dodg
prior
week
age
hodgin
shewen
earlier
induct
activ
immun
may
possibl
select
appropri
adjuv
deliveri
mucos
immun
rout
immun
stimul
complex
iscom
antigen
deliveri
adjuv
system
morein
et
al
wherein
mani
antigen
incorpor
within
surfac
small
nm
cage
like
structur
form
cholesterol
saponin
phosphatidylcholin
antigen
contain
multival
subunit
iscom
vaccin
found
within
cytosol
endosom
vesicl
antigen
present
cell
villacr
et
al
iscom
vaccin
shown
stimul
humor
cell
mediat
immun
respons
claim
overrid
downregulatori
effect
passiv
acquir
matern
antibodi
nordengrahn
et
al
hagglund
et
al
iscom
prepar
use
supernat
logphas
cultur
shown
contain
nativ
lkt
target
antigen
well
solubl
antigen
haemolytica
iscom
vaccin
use
vaccin
group
n
per
group
colostrum
fed
dairi
heifer
week
age
either
intranas
subcutan
rout
respons
vaccin
compar
unvaccin
control
group
calv
receiv
commerci
vaccin
prespons
sq
wyethfort
dodg
subcutan
week
vaccin
calv
challeng
assess
recal
respons
subcutan
vaccin
commerci
vaccin
week
age
age
respons
vaccin
might
normal
expect
three
vaccin
standard
antigen
captur
elisa
contain
concentr
lkt
equival
present
commerci
vaccin
sera
nasal
swab
collect
weekli
week
age
antibodi
respons
determin
direct
indirect
agglutin
antibodi
bacteri
surfac
antigen
elisa
isotyp
respons
lkt
antibodi
respons
express
chang
titer
week
time
initi
vaccin
adjust
antibodi
present
due
passiv
transfer
subcutan
vaccin
iscom
induc
increas
direct
agglutin
titer
serum
week
one
week
second
vaccin
titer
remain
elev
durat
studi
data
shown
vaccin
commerci
sc
vaccin
effect
titer
assay
week
age
earlier
im
formul
vaccin
shown
previous
induc
agglutin
antibodi
igm
capsular
polysaccharid
lkt
neutral
respons
calv
vaccin
week
age
hodgin
shewen
iscom
vaccin
induc
increas
serum
igg
lkt
week
follow
second
dose
fig
top
panel
rate
declin
titer
week
less
calv
receiv
prespons
compar
control
titer
control
calv
rose
week
consist
natur
induc
activ
immun
respons
commens
colon
hope
intranas
vaccin
induc
signific
chang
lkt
specif
iga
nasal
secret
week
follow
first
vaccin
week
earliest
age
succeed
induc
activ
immun
lkt
date
may
particularli
import
given
correl
nasal
iga
lkt
protect
recent
demonstr
edibl
vaccin
trial
week
age
nasal
iga
titer
begun
increas
group
fig
middl
panel
interestingli
subcutan
vaccin
iscom
vaccin
induc
increas
lkt
specif
igg
nasal
secret
could
relat
spillov
system
respons
may
reflect
home
memori
cell
nasopharynx
permit
enhanc
respons
natur
exposur
local
fig
lower
panel
thu
iscom
vaccin
commerci
vaccin
induc
immun
respons
lkt
serum
nasal
secret
follow
vaccin
week
age
preced
respons
aris
natur
exposur
evid
week
age
hope
would
earlier
respons
would
protect
calv
receiv
challeng
suffici
induc
pneumonia
week
old
period
assess
trial
studi
demonstr
possibl
detect
immun
respons
mucos
vaccin
target
nasopharyng
lymphoid
tissu
examin
antibodi
nasal
secret
also
collect
saliva
fece
mani
anim
analyz
determin
util
altern
indic
mucos
respons
could
demonstr
enhanc
respons
compar
control
sera
calv
vaccin
mucos
use
edibl
vaccin
postchalleng
would
import
protect
respons
natur
exposur
use
demonstr
immunogen
respons
vaccin
per
se
addit
though
may
adequ
stave
pneumonia
cours
natur
infect
recal
respons
adequ
provid
protect
experiment
challeng
suffici
induc
pneumonia
use
singl
bolu
exposur
therefor
may
necessari
refin
challeng
protocol
enabl
differenti
exampl
adjust
challeng
dose
anim
weight
prechalleng
serum
titer
criteria
addit
import
continu
examin
immun
respons
mucos
antigen
exposur
improv
understand
factor
lead
stimul
paramet
reflect
stimul
assist
find
new
innov
mean
enhanc
respons
includ
adjuv
deliveri
system
improv
method
detect
immunogen
author
p
shewen
coauthor
patent
protect
commerci
vaccin
prespons
receiv
loyalti
revenu
wyetfort
dodg
relat
vaccin
current
hold
contract
dow
agrosci
fund
unrel
project
except
coauthor
financi
person
relationship
peopl
organ
could
inappropri
influenc
bia
paper
entitl
challeng
mucos
vaccin
cattl
isol
unit
excel
care
calv
natur
scienc
engin
research
council
canada
ontario
ministri
agricultur
food
rural
affair
ontario
cattlemen
associ
agricultur
adapt
council
dow
agrosci
fund
variou
portion
research
